Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood protein may reveal how severe carpal tunnel syndrome is

NCT ID NCT07791316

Knowledge-focused Sponsor: Kanuni Sultan Suleyman Training and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time

Summary

Researchers are testing whether a blood protein called GDF-15 is higher in people with carpal tunnel syndrome than in people without it. They will compare GDF-15 levels with symptom scores and nerve test results in about 60 adults. The goal is to see if this protein could serve as a simple marker of how severe the condition is.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If GDF-15 levels track with carpal tunnel severity, the protein could become a simple blood test to help gauge the condition or guide treatment decisions.
What could go wrong
This is a small observational study, so it can only show links, not cause and effect. The findings may not hold up in larger or more diverse groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults aged 18-65 years, including patients with clinically and electrophysiologically confirmed idiopathic carpal tunnel syndrome and asymptomatic controls.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-65 years. * Written informed consent. * For the patient group: idiopathic carpal tunnel syndrome confirmed by clinical and electrophysiological evaluation. * For the control group: asymptomatic individuals without a previous diagnosis of carpal tunnel syndrome and without clinical signs of carpal tunnel syndrome. Exclusion Criteria: * Diabetes mellitus. * Hypothyroidism. * Rheumatoid arthritis or other inflammatory rheumatic diseases. * Pregnancy. * Cervical radiculopathy or polyneuropathy. * Previous carpal tunnel or wrist surgery. * History of wrist trauma or fracture. * Corticosteroid injection into the carpal tunnel within the previous 3 months. * Malignancy. * Chronic kidney or liver disease. * Active infection or autoimmune disease. * Serious systemic conditions that may affect serum GDF-15 levels.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Carpal tunnel syndrome are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carpal tunnel syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Carpal tunnel syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.